Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.

Autor: Conroy F; Department of Medicine, UMass Chan Medical School, Worcester, MA, 01605, USA., Miller R; Department of Medicine, UMass Chan Medical School, Worcester, MA, 01605, USA., Alterman JF; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Hassler MR; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Echeverria D; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Godinho BMDC; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Knox EG; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Sapp E; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA., Sousa J; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Yamada K; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Mahmood F; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA., Boudi A; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA., Kegel-Gleason K; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA., DiFiglia M; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA., Aronin N; Department of Medicine, UMass Chan Medical School, Worcester, MA, 01605, USA.; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA., Khvorova A; RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA, 01605, USA. anastasia.khvorova@umassmed.edu., Pfister EL; Department of Medicine, UMass Chan Medical School, Worcester, MA, 01605, USA. edith.pfister@umassmed.edu.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 Oct 03; Vol. 13 (1), pp. 5802. Date of Electronic Publication: 2022 Oct 03.
DOI: 10.1038/s41467-022-33061-x
Abstrakt: Small interfering RNAs are a new class of drugs, exhibiting sequence-driven, potent, and sustained silencing of gene expression in vivo. We recently demonstrated that siRNA chemical architectures can be optimized to provide efficient delivery to the CNS, enabling development of CNS-targeted therapeutics. Many genetically-defined neurodegenerative disorders are dominant, favoring selective silencing of the mutant allele. In some cases, successfully targeting the mutant allele requires targeting single nucleotide polymorphism (SNP) heterozygosities. Here, we use Huntington's disease (HD) as a model. The optimized compound exhibits selective silencing of mutant huntingtin protein in patient-derived cells and throughout the HD mouse brain, demonstrating SNP-based allele-specific RNAi silencing of gene expression in vivo in the CNS. Targeting a disease-causing allele using RNAi-based therapies could be helpful in a range of dominant CNS disorders where maintaining wild-type expression is essential.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: